Literature DB >> 21483453

p53 Spreads out further: suppression of EMT and stemness by activating miR-200c expression.

Jörg Schubert1, Thomas Brabletz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21483453      PMCID： PMC3203673          DOI： 10.1038/cr.2011.62

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  17 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

Review 2.  Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors:  Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

4.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

6.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

7.  The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.

Authors:  Manav Korpal; Esther S Lee; Guohong Hu; Yibin Kang
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

8.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.

Authors:  Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2008-03-30       Impact factor: 28.824

9.  p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.

Authors:  Chun-Ju Chang; Chi-Hong Chao; Weiya Xia; Jer-Yen Yang; Yan Xiong; Chia-Wei Li; Wen-Hsuan Yu; Sumaiyah K Rehman; Jennifer L Hsu; Heng-Huan Lee; Mo Liu; Chun-Te Chen; Dihua Yu; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2011-02-20       Impact factor: 28.824

10.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807
View more
  25 in total

Review 1.  Regulation of senescence by microRNA biogenesis factors.

Authors:  Kotb Abdelmohsen; Subramanya Srikantan; Min-Ju Kang; Myriam Gorospe
Journal:  Ageing Res Rev       Date:  2012-01-28       Impact factor: 10.895

2.  Hepatocyte nuclear factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibition of epithelial-mesenchymal transition.

Authors:  Xin-Wang Yuan; Dong-Mei Wang; Ying Hu; Yun-Neng Tang; Wei-Wei Shi; Xiao-Jie Guo; Jian-Guo Song
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

Review 3.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

Review 4.  Epithelial-to-mesenchymal transition in tumor progression.

Authors:  Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2017-05-30       Impact factor: 3.064

5.  CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.

Authors:  Zhao-Ru Dong; Ai-Wu Ke; Tao Li; Jia-Bing Cai; Ya-Fei Yang; Wei Zhou; Guo-Ming Shi; Jia Fan
Journal:  Mol Cancer       Date:  2021-05-13       Impact factor: 27.401

6.  TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes.

Authors:  Danila Coradini; Marco Fornili; Federico Ambrogi; Patrizia Boracchi; Elia Biganzoli
Journal:  J Biomed Biotechnol       Date:  2012-07-30

7.  Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes.

Authors:  Jinjin Zou; Hesan Luo; Qin Zeng; Zhongyi Dong; Dehua Wu; Li Liu
Journal:  J Transl Med       Date:  2011-06-25       Impact factor: 5.531

Review 8.  The evolving concept of cancer and metastasis stem cells.

Authors:  Irène Baccelli; Andreas Trumpp
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539

9.  PTTG2 silencing results in induction of epithelial-to-mesenchymal transition and apoptosis.

Authors:  C Méndez-Vidal; M del Mar Gámez-Del Estal; M A Moreno-Mateos; A G Espina-Zambrano; B Torres; J A Pintor-Toro
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

10.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins.

Authors:  Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.